[Source: The Phoenix Business Journal] – Apthera Inc., a Scottsdale-based biotech company, has named Mark Schwartz president and CEO. He replaces Charles Morgan, who resigned in September.
Most recently, Schwartz was president and CEO of San Mateo, Calif.-based Bayhill Therapeutics Inc., where he helped raise more than $100 million in venture capital and philanthropic funding for the company’s clinical programs and therapeutic platform.
Before that, he was president and CEO of Hayward, Calif.-based Calyx Therapeutics Inc., where he led a $30 million institutional round to develop anti-inflammatory compounds.
For more information: Apthera names Schwartz president and CEO